Navigation Links
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Date:3/26/2008

QUEBEC CITY, March 26 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced with its flagship product candidate, cetrorelix, the Company's lead luteinizing hormone-releasing hormone (LHRH) antagonist, in the second efficacy study of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate.

"We are very pleased to be on track with our Phase 3 clinical program for cetrorelix in BPH," said David J. Mazzo, Ph.D., President and CEO, Aeterna Zentaris. "Based on our new understanding of the multiple processes involved in the development of BPH and its symptoms, cetrorelix may offer a novel therapeutic approach to doctors and patients currently making trade-offs in care. We look forward to continuing our investigation of cetrorelix in this comprehensive clinical program."

The study, titled, "Cetrorelix pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", will involve approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This Phase 3 trial, conducted in Europe under the supervision of lead investigator, Prof. Dr. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, is part of the Company's Phase 3 program with cetrorelix being studied in approximately 1,500 patients in North America and Europe in men with symptomatic BPH.

About the Phase 3 Program with Cetrorelix in BPH

The first multi-center efficacy study for which first patient rand
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
2. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
5. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
6. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. AEterna Zentaris Announces Outcome of Managements Strategic Review
9. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
10. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
11. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply Chain Resiliency ... and resiliency practitioners with luminaries and thought leaders to advance the professional discipline ... their innovations and performance excellence. At that time its principle sponsor, Resilinc ...
(Date:8/31/2015)... , Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $5.7 million. The orders are for air emission abatement projects in ... note is a large order for a municipality in the ... be replacing a competitor,s system that failed to meet the ... engineered solutions," said Derek S. Webb , President and ...
(Date:8/31/2015)... ... August 31, 2015 , ... In recent years, biodegradable ... as low carbon footprints and compostability. These properties can help in limiting the ... the basis of applications, the market for biodegradable plastics can be broadly segmented ...
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics ... company announces that the Company,s lead antibody, HuMab 5B1, ... five separate presentations during the upcoming World Molecular Imaging ... September 2-5, 2015. Researchers from the Department of ... present results on the use of MabVax,s lead antibody ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
... (OTC Bulletin Board: CSBR ), a company engaged ... data to enhance the value of oncology drugs, today announced ... July 31, 2010.  Full details of the Company,s financial results ... www.championsbiotechnology.com . Total revenues for the first quarter ...
... Form of... -- REYKJAVIK, Iceland, September 13, 2010 ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Trial Amended ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 4deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 2deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 3deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 4deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 5deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 6deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 7deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 8Resverlogix's Phase 2 ASSURE Trial Amended 2Resverlogix's Phase 2 ASSURE Trial Amended 3Resverlogix's Phase 2 ASSURE Trial Amended 4Resverlogix's Phase 2 ASSURE Trial Amended 5Resverlogix's Phase 2 ASSURE Trial Amended 6Resverlogix's Phase 2 ASSURE Trial Amended 7
(Date:8/31/2015)... , August 31, 2015 Growing ... technology in government digitization projects to drive India ... recently published TechSci Research report, " India Biometrics Market Forecast ... is projected to grow at a CAGR of ... is anticipated on account of extensive use of biometric technology ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has announced ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.23 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/28/2015)... 28, 2015 According to a ... by Assessment Type (Pen & Paper Based, Hosted, Biometrics), ... Learning, Academic Research), Vertical and Region - Global Forecast ... Market to grow from USD 2.4 Billion in 2015 ... Annual Growth Rate (CAGR) of 25.6% from 2015 to ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4
... 2009) As stroma the supportive framework of the prostate ... genes occur that induce the formation of new structures such as ... College of Medicine in a report that appears in the current ... this study, using special techniques and gene chips that allowed them ...
... Merck Irving S. Sigal Memorial Award is being presented ... Infectious Disease Initiative at the Broad Institute of MIT ... Medicine at Harvard Medical School. Sponsored by Merck Research ... presented in memory of Irving S. Sigal, who was ...
... technology - which makes plants significantly more resistant to ... US agricultural company Becker Underwood in collaboration with Plant ... with jasmonic acid - a chemical naturally produced by ... attack. But crops treated with the chemical don,t grow ...
Cached Biology News:Gene activity reveals dynamic stroma microenvironment in prostate cancer 2Gene activity reveals dynamic stroma microenvironment in prostate cancer 3Natural seed treatment could drastically cut pesticide use 2
...
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Biology Products: